CTLA4 and melanoma: Immune checkpoint inhibitors, which target inhibitory pathways such as PD-1/PD-L1 and CTLA-4, have revolutionized the treatment of several solid tumors, including NSCLC, melanoma, renal cell carcinoma, and more.